Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007259333 | Thyroid | ATC | reactive oxygen species metabolic process | 112/6293 | 239/18723 | 1.34e-05 | 1.28e-04 | 112 |
GO:005109022 | Thyroid | ATC | regulation of DNA-binding transcription factor activity | 190/6293 | 440/18723 | 1.49e-05 | 1.39e-04 | 190 |
GO:001931814 | Thyroid | ATC | hexose metabolic process | 111/6293 | 237/18723 | 1.51e-05 | 1.41e-04 | 111 |
GO:200102114 | Thyroid | ATC | negative regulation of response to DNA damage stimulus | 46/6293 | 81/18723 | 1.51e-05 | 1.41e-04 | 46 |
GO:000736915 | Thyroid | ATC | gastrulation | 90/6293 | 185/18723 | 1.54e-05 | 1.43e-04 | 90 |
GO:000762325 | Thyroid | ATC | circadian rhythm | 100/6293 | 210/18723 | 1.67e-05 | 1.54e-04 | 100 |
GO:000636712 | Thyroid | ATC | transcription initiation from RNA polymerase II promoter | 44/6293 | 77/18723 | 1.86e-05 | 1.70e-04 | 44 |
GO:009873213 | Thyroid | ATC | macromolecule deacylation | 61/6293 | 116/18723 | 1.89e-05 | 1.72e-04 | 61 |
GO:190225332 | Thyroid | ATC | regulation of intrinsic apoptotic signaling pathway by p53 class mediator | 21/6293 | 29/18723 | 2.21e-05 | 1.96e-04 | 21 |
GO:004592622 | Thyroid | ATC | negative regulation of growth | 115/6293 | 249/18723 | 2.34e-05 | 2.06e-04 | 115 |
GO:006014823 | Thyroid | ATC | positive regulation of posttranscriptional gene silencing | 22/6293 | 31/18723 | 2.35e-05 | 2.06e-04 | 22 |
GO:007148022 | Thyroid | ATC | cellular response to gamma radiation | 22/6293 | 31/18723 | 2.35e-05 | 2.06e-04 | 22 |
GO:000599615 | Thyroid | ATC | monosaccharide metabolic process | 118/6293 | 257/18723 | 2.56e-05 | 2.20e-04 | 118 |
GO:001033217 | Thyroid | ATC | response to gamma radiation | 34/6293 | 56/18723 | 2.92e-05 | 2.45e-04 | 34 |
GO:003461228 | Thyroid | ATC | response to tumor necrosis factor | 116/6293 | 253/18723 | 3.22e-05 | 2.68e-04 | 116 |
GO:003030813 | Thyroid | ATC | negative regulation of cell growth | 90/6293 | 188/18723 | 3.35e-05 | 2.78e-04 | 90 |
GO:000320512 | Thyroid | ATC | cardiac chamber development | 79/6293 | 161/18723 | 3.39e-05 | 2.80e-04 | 79 |
GO:000600616 | Thyroid | ATC | glucose metabolic process | 93/6293 | 196/18723 | 3.85e-05 | 3.14e-04 | 93 |
GO:004886321 | Thyroid | ATC | stem cell differentiation | 97/6293 | 206/18723 | 3.88e-05 | 3.15e-04 | 97 |
GO:000963634 | Thyroid | ATC | response to toxic substance | 119/6293 | 262/18723 | 4.30e-05 | 3.48e-04 | 119 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
TP53 | MSC | Breast | DCIS | ATP1B2,CTNNB1,F2R, etc. | 1.47e-02 | |
TP53 | FIB | Breast | Healthy | ATP1B2,CTNNB1,F2R, etc. | 4.25e-02 | |
TP53 | FIB | Breast | Precancer | ATP1B2,CTNNB1,F2R, etc. | 1.56e-02 | |
TP53 | ASC | Colorectum | ADJ | CATSPERE,AP000446.1,TMEM69, etc. | 1.30e-01 | |
TP53 | TAC | Colorectum | Healthy | ESYT1,ATAD5,GNL3, etc. | 7.42e-02 | |
TP53 | CD8TEXINT | Lung | AAH | APOLD1,RAB27A,PHACTR2-AS1, etc. | 3.56e-01 | |
TP53 | TH1 | Lung | Healthy | TRAT1,MRPL43,LSM14A, etc. | 8.15e-03 | |
TP53 | CD8TCM | Lung | IAC | TTC4,ELMOD3,RNASE1, etc. | 4.42e-02 | |
TP53 | CD8TEFF | Lung | IAC | TTC4,ELMOD3,RNASE1, etc. | 3.87e-02 | |
TP53 | PVA | Lung | Healthy | HDX,LINC00960,NHEJ1, etc. | 1.10e-01 | |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TP53 | SNV | Missense_Mutation | rs28934578 | c.524N>A | p.Arg175His | p.R175H | P04637 | protein_coding | tolerated(0.11) | benign(0.319) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TP53 | SNV | Missense_Mutation | | c.398N>A | p.Met133Lys | p.M133K | P04637 | protein_coding | deleterious(0) | benign(0.061) | TCGA-A1-A0SK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
TP53 | SNV | Missense_Mutation | rs121912666 | c.659A>G | p.Tyr220Cys | p.Y220C | P04637 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | | SD |
TP53 | SNV | Missense_Mutation | rs28934576 | c.818N>A | p.Arg273His | p.R273H | P04637 | protein_coding | tolerated(0.13) | possibly_damaging(0.643) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
TP53 | SNV | Missense_Mutation | | c.623N>G | p.Asp208Gly | p.D208G | P04637 | protein_coding | deleterious(0.04) | probably_damaging(0.988) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
TP53 | SNV | Missense_Mutation | rs121912657 | c.814N>A | p.Val272Met | p.V272M | P04637 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
TP53 | SNV | Missense_Mutation | rs28934576 | c.818G>T | p.Arg273Leu | p.R273L | P04637 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
TP53 | SNV | Missense_Mutation | | c.691A>C | p.Thr231Pro | p.T231P | P04637 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-A2-A0CS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
TP53 | SNV | Missense_Mutation | rs587780073 | c.701N>G | p.Tyr234Cys | p.Y234C | P04637 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TP53 | SNV | Missense_Mutation | rs148924904 | c.488N>G | p.Tyr163Cys | p.Y163C | P04637 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0ST-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7157 | TP53 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, DRUG RESISTANCE, TRANSPORTER | | CAULIBUGULONE D | CAULIBUGULONE D | |
7157 | TP53 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, DRUG RESISTANCE, TRANSPORTER | | fluorouracil | FLUOROURACIL | |
7157 | TP53 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, DRUG RESISTANCE, TRANSPORTER | | CID 867101 | CHEMBL406557 | |
7157 | TP53 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, DRUG RESISTANCE, TRANSPORTER | | SJ000276790 | CHEMBL602922 | |
7157 | TP53 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, DRUG RESISTANCE, TRANSPORTER | | OLEOYL DOPAMINE | OLEOYL DOPAMINE | |
7157 | TP53 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, DRUG RESISTANCE, TRANSPORTER | | DNDI1417085 | CHEMBL1522984 | |
7157 | TP53 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, DRUG RESISTANCE, TRANSPORTER | | DNDI1340257 | CHEMBL1702181 | |
7157 | TP53 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, DRUG RESISTANCE, TRANSPORTER | | TEBUFENPYRAD | TEBUFENPYRAD | |
7157 | TP53 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, DRUG RESISTANCE, TRANSPORTER | | CTX-1 | | 26883273 |
7157 | TP53 | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, DRUGGABLE GENOME, KINASE, DRUG RESISTANCE, TRANSPORTER | | ZM-336372 | CHEMBL186526 | |